DHA derivatives of fish oil as dietary supplements: a nutrition-based drug discovery approach for therapies to prevent metabolic cardiotoxicity.
BACKGROUND
During the early 1970s, Danish physicians Jorn Dyerberg and colleagues observed that Greenland Eskimos consuming fatty fishes exhibited low incidences of heart disease. Fish oil is now one of the most commonly consumed dietary supplements. In 2004, concentrated fish oil was approved as a drug by the FDA for the treatment of hyperlipidemia. Fish oil contains two major omega-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). With advancements in lipid concentration and purification techniques, EPA- or DHA-enriched products are now commercially available, and the availability of these components in isolation allows their individual effects to be examined. Newly synthesized derivatives and endogenously discovered metabolites of DHA exhibit therapeutic utility for obesity, metabolic syndrome and cardiovascular disease.


METHODS
This review summarizes our current knowledge on the distinct effects of EPA and DHA to prevent metabolic syndrome and reduce cardiotoxicity risk. Since EPA is an integral component of fish oil, we will briefly review EPA effects, but our main theme will be to summarize effects of the DHA derivatives that are available today. We focus on using nutrition-based drug discovery to explore the potential of DHA derivatives for the treatment of obesity, metabolic syndrome and cardiovascular diseases.


CONCLUSIONS
The safety and efficacy evaluation of DHA derivatives will provide novel biomolecules for the drug discovery arsenal. Novel nutritional-based drug discoveries of DHA derivatives or metabolites may provide realistic and alternative strategies for the treatment of metabolic and cardiovascular disease.
The University of Texas Health Science Center at San Antonio, Division of Geriatrics, Gerontology and Palliative Medicine, Department of Medicine, San Antonio, TX 78245, USA.
Yonggang
Y
Ma
Merry L
ML
Lindsey
Ganesh V
GV
Halade
D000818:Animals; D019587:Dietary Supplements; D004281:Docosahexaenoic Acids / Q000494:pharmacology* / Q000627:therapeutic use*; D055808:Drug Discovery / Q000379:methods*; D005395:Fish Oils / Q000494:pharmacology* / Q000627:therapeutic use*; D006331:Heart Diseases / Q000378:metabolism / Q000517:prevention & control*; D006801:Humans; D009752:Nutritional Status
D005395:Fish Oils; D004281:Docosahexaenoic Acids